Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Galipeau

Showing results (11-20 of 193) with videos related to

Pageof 20
Sort By:
Immunotherapy|July 20, 2010
GIFT15 fusokine to foil immunity's folliesMoutih Rafei, Jacques Galipeau
Infectious Disorders Drug Targets|March 8, 2012
Reprogramming of B cells into regulatory cells with engineered fusokinesJiusheng Deng, Jacques Galipeau
Cytotherapy|January 17, 2015
The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteriaJacques Galipeau, Mauro Krampera
Oncoimmunology|June 22, 2012
FIST, a sword and shield fusokine for cancer immunotherapyClaudia Penafuerte, Jacques Galipeau
Journal of Cellular Physiology|March 2, 2012
New insights on translational development of mesenchymal stromal cells for suppressor therapyMoïra François, Jacques Galipeau
Oncoimmunology|May 6, 2015
B cells for cancer immunotherapyJiusheng Deng, Jacques Galipeau
Critical Reviews in Immunology|November 19, 2010
A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseasesMoutih Rafei, Jacques Galipeau
Methods in Molecular Biology (Clifton, N.J.)|July 26, 2002
Green fluorescent protein in retroviral vector constructs as marker and reporter of gene expression for cell and gene therapy applicationsNicoletta Eliopoulos, Jacques Galipeau
Bulletin Du Cancer|September 19, 2006
[The use of mesenchymal stromal cells in oncology and cell therapy]Sandra Pommey, Jacques Galipeau
Medecine Sciences : M/S|March 2, 2010
[A chimeric cytokine to help autoimmune diseases]Moutih Rafei, Jacques Galipeau
Pageof 20

Showing results (11-20 of 193) with videos related to

Sort By:
Pageof 20
Immunotherapy|July 20, 2010
GIFT15 fusokine to foil immunity's folliesMoutih Rafei, Jacques Galipeau
Infectious Disorders Drug Targets|March 8, 2012
Reprogramming of B cells into regulatory cells with engineered fusokinesJiusheng Deng, Jacques Galipeau
Cytotherapy|January 17, 2015
The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteriaJacques Galipeau, Mauro Krampera
Oncoimmunology|June 22, 2012
FIST, a sword and shield fusokine for cancer immunotherapyClaudia Penafuerte, Jacques Galipeau
Journal of Cellular Physiology|March 2, 2012
New insights on translational development of mesenchymal stromal cells for suppressor therapyMoïra François, Jacques Galipeau
Oncoimmunology|May 6, 2015
B cells for cancer immunotherapyJiusheng Deng, Jacques Galipeau
Critical Reviews in Immunology|November 19, 2010
A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseasesMoutih Rafei, Jacques Galipeau
Methods in Molecular Biology (Clifton, N.J.)|July 26, 2002
Green fluorescent protein in retroviral vector constructs as marker and reporter of gene expression for cell and gene therapy applicationsNicoletta Eliopoulos, Jacques Galipeau
Bulletin Du Cancer|September 19, 2006
[The use of mesenchymal stromal cells in oncology and cell therapy]Sandra Pommey, Jacques Galipeau
Medecine Sciences : M/S|March 2, 2010
[A chimeric cytokine to help autoimmune diseases]Moutih Rafei, Jacques Galipeau
Pageof 20